Analysts Set Liquidia Co. (NASDAQ:LQDA) PT at $24.67

Liquidia Co. (NASDAQ:LQDA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $24.67.

LQDA has been the subject of a number of research analyst reports. Raymond James raised Liquidia from an "outperform" rating to a "strong-buy" rating in a report on Monday, August 19th. BTIG Research lowered their target price on shares of Liquidia from $29.00 to $25.00 and set a "buy" rating on the stock in a research note on Monday, August 19th. Lifesci Capital assumed coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price target on the stock. Bank of America decreased their price objective on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating for the company in a report on Tuesday, August 20th. Finally, Needham & Company LLC restated a "buy" rating and issued a $25.00 target price on shares of Liquidia in a report on Monday, August 19th.

Liquidia Trading Up 0.2 %

LQDA traded up $0.02 during midday trading on Monday, reaching $11.03. The company's stock had a trading volume of 645,655 shares, compared to its average volume of 993,637. Liquidia has a 1 year low of $6.06 and a 1 year high of $16.99. The stock's 50-day moving average is $10.18 and its 200-day moving average is $11.75. The firm has a market capitalization of $846.99 million, a price-to-earnings ratio of -7.03 and a beta of 0.22.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The firm had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. As a group, equities research analysts forecast that Liquidia will post -1.69 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In related news, Director Caligan Partners Lp acquired 150,000 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the purchase, the director now owns 6,994,997 shares in the company, valued at $66,522,421.47. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Liquidia news, Director Caligan Partners Lp acquired 150,000 shares of the stock in a transaction dated Friday, August 30th. The shares were acquired at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the transaction, the director now directly owns 6,994,997 shares of the company's stock, valued at approximately $66,522,421.47. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Rajeev Saggar sold 2,260 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the sale, the insider now owns 207,383 shares of the company's stock, valued at $2,304,025.13. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock worth $236,021 in the last three months. Corporate insiders own 30.10% of the company's stock.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently modified their holdings of the stock. Patient Square Capital LP purchased a new stake in Liquidia in the 1st quarter worth $105,942,000. Vanguard Group Inc. lifted its position in shares of Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company's stock worth $42,587,000 after buying an additional 43,352 shares in the last quarter. Farallon Capital Management LLC bought a new position in Liquidia during the first quarter valued at approximately $30,311,000. Whitefort Capital Management LP grew its holdings in Liquidia by 45.8% during the 1st quarter. Whitefort Capital Management LP now owns 337,607 shares of the company's stock valued at $4,980,000 after buying an additional 106,049 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company's stock worth $3,396,000 after acquiring an additional 125,315 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).